CD8A and neoplasm: Pharmacological blockade of A2aR by SCH58261 delayed the tumour growth in the HNSCC mouse model and significantly decreased the population of CD4+Foxp3+ Tregs and enhanced the anti-tumour response of CD8+ T cells (Ma et al. 2017).